Targeting inflammation to treat depression

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of General Psychiatry.

"Inflammation is the body's natural response to infection or wounding, says Andrew H. Miller, MD, senior author for the study and professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine. "However when prolonged or excessive, inflammation can damage many parts of the body, including the brain."

Prior studies have suggested that depressed people with evidence of high inflammation are less likely to respond to traditional treatments for the disorder, including anti-depressant medications and psychotherapy. This study was designed to see whether blocking inflammation would be a useful treatment for either a wide range of people with difficult-to-treat depression or only those with high levels of inflammation.

The study employed infliximab, one of the new biologic drugs used to treat autoimmune and such as rheumatoid arthritis and . A biologic drug copies the effects of substances naturally made by the body's immune system. In this case, the drug was an antibody that blocks (TNF), a key molecule in inflammation that has been shown to be elevated in some .

Study participants all had and were moderately resistant to conventional antidepressant treatment. Each participant was assigned either to infliximab or to a non-active .

When investigators looked at the results for the group as a whole, no significant differences were found in the improvement of between the drug and placebo groups. However, when the subjects with high inflammation were examined separately, they exhibited a much better response to infliximab than to placebo.

Inflammation in this study was measured using a simple blood test that is readily available in most clinics and hospitals and measures C-reactive protein or CRP. The higher the CRP, the higher the inflammation, and the higher the likelihood of responding to the drug.

"The prediction of an antidepressant response using a simple blood test is one of the holy grails in psychiatry," says Miller. "This is especially important because the blood test not only measured what we think is at the root cause of depression in these patients, but also is the target of the drug."

"This is the first successful application of a biologic therapy to depression," adds Charles L. Raison, MD, first author of the study. "The study opens the door to a host of new approaches that target the immune system to treat psychiatric diseases." Raison, formerly at Emory, is now associate professor in the Department of Psychiatry at the University of Arizona College of Medicine – Tucson.

Related Stories

Inflammation in depression: Chicken or egg?

Jan 05, 2012

An important ongoing debate in the field of psychiatry is whether inflammation in the body is a consequence of or contributor to major depression. A new study in Biological Psychiatry has attempted to resolve the issue.

Depression could be evolutionary byproduct of immune system

Mar 01, 2012

Depression is common enough – afflicting one in ten adults in the United States – that it seems the possibility of depression must be "hard-wired" into our brains. This has led biologists to propose several theories ...

Are depressed people too clean?

Dec 07, 2010

In an effort to pinpoint potential triggers leading to inflammatory responses that eventually contribute to depression, researchers are taking a close look at the immune system of people living in today's cleaner modern society.

Recommended for you

Poor mother-baby bonding passed to next generation

4 hours ago

Trust pathways in the brain are set in infancy and passed on from mother to child, according to landmark UNSW-led research. The work relates to oxytocin levels in new mothers and proves for the first time ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

jbone
5 / 5 (3) Sep 03, 2012
They seem to have pills for everything but when you want to know the actual cause of the inflammation you will be bounced around for years.
alfie_null
not rated yet Sep 04, 2012
They seem to have pills for everything but when you want to know the actual cause of the inflammation you will be bounced around for years.

Follow the money.

Preventing a malady - meh.

New medicine for malady - expensive but eventually pays out.

Repurposing an existing medicine (already been through the expensive approval process) - jackpot!

You also get bonus points if the treatment is chronic.
antonima
not rated yet Sep 04, 2012
Hey, isn't it a fact that people under chronic pain develop depression? And then they are saying 'if we can reduce pain [inflammation] our antidepressants are more likely to work'. Thats kind of obvious isn't it?

"Prior studies have suggested that depressed people with evidence of high inflammation are less likely to respond to traditional treatments for the disorder, including anti-depressant medications and psychotherapy."

Well duh, they are still in severe pain.

Thats just my take on it, I could be completely wrong. Inflammation and pain aren't necessarily in the same category of symptoms.